Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases
Arteriosclerosis, Thrombosis, and Vascular Biology · 2026-05 · 46 (5)
DOI: 10.1161/atvbaha.126.324257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026-05. Verfasst von Diandra M Mastrogiacomo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Lymphatic Vessels, Endothelial Cells, Lymphangiogenesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Lymphatic malformations are lesions that can be due to inherited or somatic mutations, and they lead to a defective lymphatic vasculature. Activating KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations have been identified recently in patients with lymphatic malformation with lymphedema, chylous ascites, or life-threatening chylothorax. In a lymphatic malformation mouse model, KRAS mutations are associated with a loss of lymphatic valves, which has been proposed to cause chylothorax via retrograde lymph flow into the pleural space. However, the mechanisms underlying the loss of lymphatic valves are unknown. METHODS: To investigate the mechanisms leading to valve loss, we combined the lymphatic-specific and tamoxifen-inducible Flt4CreER T2 with Kras-loxP-stop-loxP-G12D ( Kras +/G12D ) mice and Prox1GFP reporter mice to induce the restricted expression of KRAS-G12D and enable valve quantification in postnatal pups. Human dermal lymphatic endothelial cells expressing KRAS-G12D were probed for changes in mRNA and protein expression with quantitative real-time polymerase chain reaction, Western blot, and gel zymography, and mechanistic studies were performed using 3-dimensional cell culture in collagen matrices. RESULTS: Our data showed that lymphatic-specific expression of KRAS-G12D significantly attenuated valve development in the mesentery, diaphragm, and ear skin. Quantitative real-time polymerase chain reaction, Western blot, and gel zymography using human dermal lymphatic endothelial cells expressing KRAS-G12D revealed the upregulation of the PA (plasminogen activator) pathway and MMPs (matrix metalloproteinases). The MMPs were sufficiently activated by plasmin, the product of the PA pathway, in human dermal lymphatic endothelial cells grown in a 3-dimensional collagen matrix, indicating a role for MMPs in the degradation of valve ECM (extracellular matrix) core. Furthermore, a broad-spectrum MMP inhibitor given to Flt4CreER T2 ;Kras +/G12D mice rescued lymphatic valve development. CONCLUSIONS: We conclude that hyperactive KRAS signaling upregulates MMPs that become excessively activated by the upregulation of the PA pathway. MMPs then degrade the lymphatic valve ECM core, preventing valve formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).
- Department of Surgery, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas (M.T.D.).
ORCID-Profile: Diandra M Mastrogiacomo, Abbigail Price, Yuting Fu, Richa Banerjee, Luz A Knauer, Ying Yang, George E Davis, Joshua P Scallan
Förderung
- NHLBI NIH HHS
Zitieren
APA
Mastrogiacomo, D. M., Price, A., Fu, Y., Banerjee, R., Knauer, L. A., Li, K., Yang, Y., Davis, G. E., Dellinger, M. T., & Scallan, J. P. (2026). Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology, 46(5). https://doi.org/10.1161/atvbaha.126.324257
Vancouver
Mastrogiacomo DM, Price A, Fu Y, Banerjee R, Knauer LA, Li K, et al. Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026;46(5). doi:10.1161/atvbaha.126.324257
BibTeX
@article{Mastrogiacomo2026,
author = {Mastrogiacomo, Diandra M and Price, Abbigail and Fu, Yuting and Banerjee, Richa and Knauer, Luz A and Li, Kunyu and Yang, Ying and Davis, George E and Dellinger, Michael T and Scallan, Joshua P},
title = {Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2026},
volume = {46},
number = {5},
doi = {10.1161/atvbaha.126.324257}
}
EUVIMED